A Phase 1, First-In-Human, Multicenter, Open-Label,Dose-Escalation and Extension Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors
Latest Information Update: 19 Mar 2025
At a glance
- Drugs GQ 1005 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Suzhou GeneQuantum Healthcare
- 14 Sep 2024 According to GeneQuantum Healthcare media release, data of a novel HER2-ADC GQ1005 in HER2-expressing or HER2- mutated advanced solid tumors from this study , presented at the World Congress on Lung Cancer (WCLC) was held in San Diego, USA.
- 10 Apr 2024 Results ( As of Oct. 13th, 2023, n=46) assessing the safety, tolerability, pharmacokinetics, and antitumor activity of GQ1005 in patients with advanced solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research
- 06 Dec 2023 New trial record